BioSpace News Archive

Immunovia AB announced that Thomas King, MD, PhD, Medical Director of Immunovia, Inc. was awarded the Presidential Poster Award at the American College of Gastroenterology Annual Scientific Meeting for the pivotal blind validation results for the IMMray™ PanCan-d test.

Agomab Therapeutics NV announced that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta pathway for the treatment of fibrosis-related disorders.

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced that it has closed a $40 million investment round.

RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced the DermaPrecise trademark for its dermal injector product portfolio.

Evelo Biosciences, Inc. today reported financial results and business highlights for the third quarter 2021.

HCW Biologics Inc. today announced that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer.

Oyster Point Pharma, Inc. today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after the market close.

Visby Medical™, a leading medical diagnostic company, announced Thomas Prescott, former president and chief executive officer of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board.

Blueprint Medicines Corporation today reported financial results and provided a business update for the third quarter ended September 30, 2021.

Ensoma today announced additions to the Company’s scientific advisory board (SAB)